| |
| |
|
| Insider
Information: |
Atwood Brian G |
| Relationship: |
Chief Executive Office... |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
157,758 |
|
|
Indirect Shares
|
20,247,283 |
|
|
| Direct
Value |
$491 |
|
|
|
Indirect Value
|
$42,652,061 |
|
|
| Total
Shares |
20,405,041 |
|
|
| Total
Value |
$42,652,553 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Welltek Incorporated |
WTKND |
Director |
2008-03-07 |
0 |
2005-02-23 |
0 |
Premium* |
|
|
Cadence Pharmaceuticals Inc |
CADX |
Director |
2006-10-30 |
0 |
2014-03-19 |
0 |
Premium* |
|
|
Helicos Biosciences Corp |
HLCSQ |
Director, 10% Owner |
2007-05-30 |
0 |
2009-09-18 |
10,709,818 |
Premium* |
|
|
Trius Therapeutics Inc |
TSRX |
Director, 10% Owner |
2010-08-06 |
0 |
2010-08-06 |
3,235,839 |
Premium* |
|
|
Clovis Oncology, Inc. |
CLVS |
Director |
2020-11-09 |
32,758 |
2020-11-09 |
127,432 |
Premium* |
|
|
Five Prime Therapeutics Inc |
FPRX |
Director |
2013-09-23 |
0 |
2013-09-23 |
1,092,152 |
Premium* |
|
|
Veracyte, Inc. |
VCYT |
Director, 10% Owner |
2013-11-04 |
0 |
2013-11-04 |
21,232 |
Premium* |
|
|
Immune Design Corp. |
IMDZ |
Director, 10% Owner |
2014-07-29 |
0 |
2014-07-29 |
2,208,210 |
Premium* |
|
|
Opgen Inc |
OPGN |
Director, 10% Owner |
|
0 |
2015-05-08 |
2,554,211 |
Premium* |
|
|
Atreca Inc |
BCEL |
Director |
|
0 |
2019-06-24 |
49,654 |
Premium* |
|
|
Phoenix Biotech Acquisition Corp. |
PBAX |
Chief Executive Office... |
2024-02-14 |
125,000 |
2024-02-14 |
248,735 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PBAX |
Phoenix Biotech Acquisiti... |
Chief Executive Officer |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
0 |
- |
|
| PBAX |
Phoenix Biotech Acquisiti... |
Chief Executive Officer |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
248,735 |
248,735 |
0 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2020-11-09 |
4 |
OE |
$3.08 |
$21,240 |
D/D |
6,896 |
32,758 |
0 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2019-08-20 |
4 |
OE |
$0.29 |
$7,500 |
D/D |
25,862 |
25,862 |
0 |
- |
|
| BCEL |
Atreca Inc |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
8,791 |
49,654 |
0 |
- |
|
| BCEL |
Atreca Inc |
Director |
– • – |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
40,863 |
|
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2017-06-26 |
4 |
A |
$0.00 |
$0 |
I/I |
5,210 |
25,577 |
0 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2015-05-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(498,696) |
2,550 |
0 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2015-05-14 |
4 |
A |
$0.00 |
$0 |
I/I |
98,291 |
20,367 |
0 |
- |
|
| OPGN |
Opgen Inc |
Director |
– • • |
2015-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
2,068,286 |
2,554,211 |
0 |
- |
|
| OPGN |
Opgen Inc |
Director |
– • • |
2015-05-08 |
4 |
B |
$6.00 |
$2,479,992 |
I/I |
413,332 |
485,925 |
2.25 |
- |
|
| OPGN |
Opgen Inc |
Director |
– • – |
2015-05-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
72,593 |
|
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • • |
2014-07-29 |
4 |
B |
$12.00 |
$2,799,996 |
I/I |
233,333 |
2,208,210 |
2.25 |
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • • |
2014-07-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,183,211 |
2,183,211 |
0 |
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • • |
2014-07-29 |
4 |
S |
$12.00 |
$2,500,008 |
I/I |
(208,334) |
1,974,877 |
0 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2014-03-27 |
4 |
A |
$0.00 |
$0 |
I/I |
12,213 |
13,355 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
Director |
– • – |
2014-03-19 |
4 |
D |
$14.00 |
$70,098,952 |
I/I |
(5,007,068) |
0 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
Director |
– • – |
2014-02-12 |
4 |
D |
$14.00 |
$5,450,130 |
I/I |
(389,295) |
10,618 |
0 |
- |
|
| CADX |
Cadence Pharmaceuticals I... |
Director |
– • – |
2014-02-12 |
4 |
OE |
$7.84 |
$5,450,117 |
I/I |
695,168 |
13,056 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • • |
2013-11-04 |
4 |
A |
$0.00 |
$0 |
I/I |
3,616,221 |
21,232 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
Director |
– • – |
2013-09-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,015,229 |
1,015,229 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
Director |
– • – |
2013-09-23 |
4 |
B |
$13.00 |
$999,999 |
I/I |
76,923 |
1,092,152 |
2.1 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • – |
2013-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,142 |
1,142 |
0 |
- |
|
| CLVS |
Clovis Oncology, Inc. |
Director |
– • • |
2011-11-16 |
4 |
B |
$0.00 |
$0 |
I/I |
665,488 |
13,600 |
2.17 |
- |
|
| TSRX |
Trius Therapeutics Inc |
Director |
– • • |
2010-08-06 |
4 |
B |
$5.00 |
$4,572,645 |
I/I |
914,529 |
3,235,839 |
2.25 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
